Shares rise after record FY23 results, maiden dividend declared.  AFT Pharmaceuticals managing director Hartley Atkinson. NZX-listed AFT Pharmaceuticals has declared a maiden dividend after record revenue to the end of March 2023, as it looks to start selling its flagship pain relief product Maxigesic into the US market early next year. The Auckland-based pharmaceutical company's share price surged 9% in early Want to read more? It's easy. Choose your best value subscription option Get two weeks free access to NBR's Premium Online Subscription, which includes full access to all of NBR's great content on any device.

https://www.nbr.co.nz/tech/aft-pharmaceuticals-hopes-to-get-us-maxigesic-sales-by-early-2024/

#nbr